RenovoRx Reports $1.1M RenovoCath Revenue in First Full Year, Confirms Strong Cash Position & Trial Progress
RNXT sits 53% above its 52-week low of $0.701.
Summary
RenovoRx reported its full year 2025 financial results, highlighting $1.1 million in revenue from its RenovoCath device in its first full year of commercialization. The company also provided a business update, confirming a strong cash position of $13 million, which includes the recently closed $10 million private placement. Furthermore, the Phase III TIGeR-PaC clinical trial is on track for enrollment completion by mid-2026, with 104 patients randomized to date, building on the recent milestone of surpassing 100 patients. This comprehensive update provides new financial metrics and positive operational progress, indicating initial market adoption for RenovoCath and a solid financial runway. Investors will be watching for continued commercialization growth and the timely completion of the TIGeR-PaC trial.
At the time of this announcement, RNXT was trading at $1.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.2M. The 52-week trading range was $0.70 to $1.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.